Get the Stockscreener App
0.365
3.81%
0.0134
IGC Pharma Inc stock is traded at $0.365, with a volume of 434.07K.
It is up +3.81% in the last 24 hours and down -10.98% over the past month.
India Globalization Capital, Inc. engages in the development and commercialization of cannabis-based therapies to treat Alzheimer's, pain, nausea, eating disorders, several end points of Parkinson's, and epilepsy in humans, dogs, and cats. The company operates through two segments, Legacy Infrastructure and Medical Cannabis Based Alternative Therapies. The Legacy Infrastructure segment trades in infrastructure commodities, such as steel and iron ore; and rents heavy equipment. The Medical Cannabis Based Alternative Therapies segment offers IGC-501 for indications of neuropathic pain; Serosapse for indications of Parkinson's and other central nervous system disorders; Caesafin for seizures in cats and dogs; and Natrinol for indications of cancer and AIDS induced nausea and vomiting, as well as Hyalolex for Alzheimer's patients. The company was founded in 2005 and is based in Bethesda, Maryland.
See More
Previous Close:
$0.3516
Open:
$0.35
24h Volume:
434.07K
Relative Volume:
0.19
Market Cap:
$33.15M
Revenue:
$1.22M
Net Income/Loss:
$-14.15M
P/E Ratio:
-1.4038
EPS:
-0.26
Net Cash Flow:
$-6.55M
1W Performance:
-1.32%
1M Performance:
-10.98%
6M Performance:
+23.31%
1Y Performance:
-2.74%
1-Day Range:
$0.35
$0.3698
1-Week Range:
$0.3481
$0.39
52-Week Range:
$0.2525
$0.48
IGC Pharma Inc Stock (IGC) Company Profile
Name
IGC Pharma Inc
Sector
Industry
Phone
301-983-0998
Address
4336 Montgomery Avenue, Bethesda, MD
Compare IGC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.365 | 31.89M | 1.22M | -14.15M | -6.55M | -0.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
IGC Pharma Inc Stock (IGC) Latest News
Using AI based signals to follow IGC Pharma Inc.Buy Signal & Growth Oriented Trade Recommendations - Newser
Risk vs reward if holding onto IGC Pharma Inc.July 2025 Catalysts & Risk Controlled Stock Pick Alerts - Newser
Can machine learning forecast IGC Pharma Inc. recoveryDividend Hike & Low Risk Investment Opportunities - Newser
Can IGC Pharma Inc. recover in the next quarterJuly 2025 Closing Moves & Fast Gain Stock Trading Tips - Newser
How to build a dashboard for IGC Pharma Inc. stock2025 EndofYear Setup & High Conviction Trade Alerts - Newser
Leading vs lagging indicators on IGC Pharma Inc. performanceJuly 2025 Institutional & Real-Time Stock Movement Alerts - Newser
Long term hold vs stop loss in IGC Pharma Inc.Wall Street Watch & Long-Term Capital Growth Ideas - Newser
Understanding IGC Pharma Inc.’s price movementEarnings Growth Report & Expert-Curated Trade Recommendations - Newser
IGC Pharma Inc. Reaches Critical Trendline SupportJuly 2025 Closing Moves & Consistent Profit Focused Trading Strategies - kangso.co.kr
IGC Pharma Inc. stock retracement – recovery analysisProfit Target & Risk Controlled Swing Alerts - Newser
Published on: 2025-08-19 15:10:24 - Newser
Key metrics from IGC Pharma Inc.’s quarterly data2025 Institutional Moves & Consistent Growth Stock Picks - Newser
IGC Pharma : Notice & Access 2025 ASM - MarketScreener
IGC Pharma : Letter to Stockholders FYE2025 Annual Report - MarketScreener
Can a trend reversal in IGC Pharma Inc. lead to recoveryPortfolio Update Summary & Reliable Entry Point Trade Alerts - Newser
IGC Pharma Reports Q1 FY2026 Financial Results, Accelerates Phase 2 Alzheimer's Trial - AInvest
Clinical-Stage Biotech IGC Pharma Cuts Costs 28%, Accelerates Alzheimer's Trial Targeting 76% Patient Need - Stock Titan
Igc Pharma’s Risky Venture: Navigating Financial Instability Amid Bitcoin Investment Plans - MSN
Volume Profile Shows Strong Base for IGC Pharma Inc.Portfolio Risk Report & Accurate Trade Setup Notifications - kangso.co.kr
Can IGC Pharma Inc. weather a recession2025 Risk Factors & AI Powered Market Trend Analysis - thegnnews.com
Evaluating IGC Pharma Inc. with trendline analysis2025 Investor Takeaways & AI Powered Market Entry Ideas - Newser
Should you avoid IGC Pharma, Inc. stock right nowTrade Performance Summary & Technical Pattern Alert System - thegnnews.com
Sector ETF performance correlation with IGC Pharma Inc.2025 Market Outlook & Momentum Based Trading Ideas - Newser
Published on: 2025-08-18 08:15:17 - kangso.co.kr
What makes IGC Pharma Inc. stock price move sharplyJuly 2025 Review & Fast Moving Market Watchlists - thegnnews.com
Can IGC Pharma Inc. stock recover from recent declineJuly 2025 Selloffs & AI Enhanced Trading Alerts - Newser
How Resilient Is IGC Pharma Inc. Stock During Economic DownturnsJuly 2025 Volume & Smart Allocation Stock Reports - Newser
IGC Pharma Inc. Bounces Off Moving Average SupportJuly 2025 Catalysts & Community Shared Stock Ideas - news-j.co.kr
Is IGC Pharma Inc. stock bottoming outFed Meeting & Risk Managed Investment Entry Signals - Newser
Igc Pharma Faces Financial Instability Amid Bitcoin Investment Plans - AInvest
Trend analysis for IGC Pharma Inc. this weekQuarterly Portfolio Review & Free Low Drawdown Momentum Trade Ideas - Newser
Chart overlay techniques for tracking IGC Pharma Inc.2025 EndofYear Setup & Verified Trade Idea Suggestions - Newser
IGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue Estimates - MSN
Bullish Candlestick Pattern Forms in IGC Pharma Inc.2025 EndofYear Setup & Technical Buy Zone Confirmations - sundaytimes.kr
IGC Pharma highlights preclinical data on IGC-M3 - MSN
Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ - GlobeNewswire
IGC Pharma Inc Stock (IGC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):